

REPROS THERAPEUTICS INC.

Form 8-K

January 10, 2008

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
Current Report Filed Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934  
Date of Report  
(Date of earliest event reported): January 10, 2008  
Repos Therapeutics Inc.  
(Exact name of registrant as specified in its charter)**

<b>Delaware</b>	<b>001-15281</b>	<b>76-0233274</b>
<b>(State or other jurisdiction of incorporation or organization)</b>	<b>(Commission File Number)</b>	<b>(I.R.S. Employer Identification No.)</b>
	<b>2408 Timberloch Place, Suite B-7 The Woodlands, Texas 77380 (Address of principal executive offices and zip code) (281) 719-3400 (Registrant's telephone number, including area code)</b>	

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

Item 7.01. Regulation FD Disclosure

Item 9.01. Financial Statements and Exhibits

SIGNATURES

EXHIBIT INDEX

Slide Show

---

**Table of Contents**

**Item 7.01. Regulation FD Disclosure**

Repros Therapeutics Inc. is furnishing herewith as Exhibit 99.1 a copy of a slide show presentation that it intends to present on Thursday, January 10, 2008, at 12:00 noon Pacific Time during the JP Morgan 26<sup>th</sup> Annual Healthcare Conference at the Westin St. Francis Hotel in San Francisco, California. These slides contain statements that are forward-looking statements subject to the cautionary statement about forward-looking statements set forth therein.

The information in this Current Report, including the Exhibit, is being furnished and shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. In addition, the information in this Current Report, including the Exhibit, shall not be incorporated by reference into any registration statement pursuant to the Securities Act of 1933

**Item 9.01. Financial Statements and Exhibits**

c. Exhibits

Exhibit

Number	Description
99.1	Repros Therapeutics Inc. slide show.

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Repros Therapeutics Inc.**

Date: January 10, 2008

By: /s/ Louis Ploth, Jr.

Louis Ploth, Jr.  
Vice President, Business Development  
and Chief Financial Officer

---

**Table of Contents**

**EXHIBIT INDEX**

Exhibit Number	Description
99.1	Repros Therapeutics Inc. Slide Show